TREK

ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
torsdag, maj 9, 2024
Chicago Medical School, Sale, University, Patient, Rutgers University, ATS, Alopecia areata, Kinetics, Skin, European Patent Convention, Research, MD, Doctor of Philosophy, Conference, KOL, Potential, ADS, Week, Patent, Data, Dupilumab, University of Rochester, Translational medicine, International Examiner, Magnetic resonance, Atopic dermatitis, Harvard Medical School, ASLN, TREK, Clutch (eggs), Interim, Biology, American Thoracic Society, Associate, Emergency medicine, EPO, SAN, COPD, Pharmaceutical industry

SAN MATEO, Calif. and SINGAPORE, May 09, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate activities.

Key Points: 
  • SAN MATEO, Calif. and SINGAPORE, May 09, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate activities.
  • Research and development expenses were $5.9 million for the first quarter of 2024 compared to $14.1 million for the first quarter of 2023.
  • General and administrative expenses were $3.4 million for the first quarter of 2024 compared to $4.0 million for the first quarter of 2023.
  • Net loss attributable to stockholders for the first quarter of 2024 was $9.9 million compared to a net loss of $19.1 million for the first quarter of 2023.

Persistent Systems hosts transitioning Special Ops vets from The Honor Foundation

Retrieved on: 
måndag, april 29, 2024
Organization, Motorola, Woman, HR, City, MANET, Persistent Systems, The Walt Disney Company, Platinum, Workforce, TREK, Tennessee Titans, Veteran, Persistent, Management

NEW YORK, April 29, 2024 /PRNewswire/ -- Persistent Systems, LLC ("Persistent"), a leader in mobile ad hoc networking (MANET) technology, hosted The Honor Foundation, a career transition program that helps U.S. Special Operations Forces veterans find their next mission in the civilian workforce.

Key Points: 
  • NEW YORK, April 29, 2024 /PRNewswire/ -- Persistent Systems, LLC ("Persistent"), a leader in mobile ad hoc networking (MANET) technology, hosted The Honor Foundation, a career transition program that helps U.S. Special Operations Forces veterans find their next mission in the civilian workforce.
  • "We were thrilled to host The Honor Foundation at our New York City headquarters," said Dr. Herbert Rubens, Founder and CEO of Persistent Systems.
  • "The Honor Foundation gave me the resume, job-hunting, and interviewing skills that led to my job at Persistent Systems," said Matthew Valko, a former U.S. Marine Special Operations Command radio transmissions operator and now a technical trainer at Persistent.
  • The Honor Foundation has organized past "TREKS" to other cities, with companies such as Facebook, Motorola, The Walt Disney Company, Google, and the Tennessee Titans.

ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
fredag, april 12, 2024
UCLA, Congress, Sale, European Patent Office, Rutgers University, Chronic obstructive pulmonary disease, Outline of health sciences, Alopecia areata, Eosinophilic bronchitis, Safety, Skin, Drug development, European Patent Convention, Research, EASI, MD, Trial of the century, COPD, KOL, ADS, DHODH, Patent, Data, Patient, Liver, Dupilumab, Translational medicine, International Examiner, Harvard Medical School, ASLN, TREK, AA, Associate, Clinical trial, Emergency medicine, EPO, SAN, Contract research organization, Pharmaceutical industry

Cash used in operations for the fourth quarter of 2023 was $7.6 million compared to $12.0 million in the same period in 2022.

Key Points: 
  • Cash used in operations for the fourth quarter of 2023 was $7.6 million compared to $12.0 million in the same period in 2022.
  • Research and development expenses were $9.6 million in the fourth quarter of 2023 compared to $10.7 million in the fourth quarter of 2022.
  • General and administrative expenses were $3.2 million in the fourth quarter of 2023 compared to $2.7 million in the fourth quarter of 2022.
  • Net loss attributable to stockholders for the fourth quarter of 2023 was $13.5 million compared to a net loss of $14.5 million for the fourth quarter of 2022.

Advantech Pioneering Tomorrow's Innovations at MODEX 2024

Retrieved on: 
torsdag, februari 29, 2024
Other Consumer, IOT (Internet of Things), Manufacturing, Retail, Aftermarket, Food Tech, Automotive, Other Technology, Artificial Intelligence, Software, Supply Chain Management, Hardware, Consumer, Data Management, Consumer Electronics, Technology, Payments, Other Retail, Other Manufacturing, ISO, SSD, Dust, Multimedia, Shock, Temperature, ADAS, Congress Center, TREK, Vibration, AI accelerator, System, Series, Safety, Wi-Fi 6, Water

Advantech , a leader in the supply chain and manufacturing industry, is thrilled to announce its participation in the highly anticipated MODEX booth C5370, taking place from March 11-14th, 2024, at the Georgia World Congress Center.

Key Points: 
  • Advantech , a leader in the supply chain and manufacturing industry, is thrilled to announce its participation in the highly anticipated MODEX booth C5370, taking place from March 11-14th, 2024, at the Georgia World Congress Center.
  • View the full release here: https://www.businesswire.com/news/home/20240229050161/en/
    TREK-60N meets the demanding performance requirements of in-vehicle applications and harsh environments and more on a single platform.
  • The TREK-60N stands out as a technological marvel, meeting the evolving demands of the computing landscape with its versatility and efficiency.
  • For more information or to set up an appointment to meet with Advantech at MODEX 2024, contact [email protected] .

ASLAN Pharmaceuticals Provides Year-End Update on Its Eblasakimab and Farudodstat Programs

Retrieved on: 
tisdag, december 12, 2023
Liver, Atopic dermatitis, Eosinophilic bronchitis, Partnership, Dermatology, ASLN, Alopecia areata, Hair loss, Disease, MD, SAN, JAK, Beacon Grand Hotel, IGA, EASI, Institutional review board, TREK, DHODH, Patient, Safety, AA, Skin

SAN MATEO, Calif. and SINGAPORE, Dec. 12, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today provided a business update and updates related to its programs, eblasakimab and farudodstat.

Key Points: 
  • SAN MATEO, Calif. and SINGAPORE, Dec. 12, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today provided a business update and updates related to its programs, eblasakimab and farudodstat.
  • “Throughout 2023, ASLAN made major progress on multiple fronts – advancing both of our lead programs, eblasakimab and farudodstat in Phase 2 testing, and establishing business development collaborations to further the development and utilization of eblasakimab,” said Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals.
  • ASLAN will provide an update in early 2024 on the timing of the expected topline readout from the study in 2024.
  • Publication and presentation of further data from the TREK-AD study of eblasakimab, including biomarker data, and on farudodstat at major congresses.

Last chance to win one of four replica championship bicycles

Retrieved on: 
tisdag, september 19, 2023
Christophe, British Championship, Freedom, Elite, Education, Health, World Bicycle Relief, Edinburgh Global Partnerships, World cup, UCI Cycling World Championships, Woman, Carbon, Courtney, Athlete, UCI, Tour de France Femmes, SRAM, Engineering, TREK, Kate Courtney, Safety, Empowerment, Bicycle

CHICAGO, Sept. 19, 2023 /PRNewswire/ --Women's cycling is currently enjoying a remarkable surge in popularity and success, thanks in no small part to the achievements of four exceptional women. On a bicycle women can achieve amazing things, as demonstrated by the incredible careers of professional cyclists Annemiek van Vleuten, Marianne Vos, Kate Courtney, and Evie Richards.

Key Points: 
  • Each of these remarkable athletes, in collaboration with their brand sponsors, provided a replica of the bicycle they used during the Championships.
  • World Bicycle Relief is a global nonprofit organization dedicated to providing access to education, healthcare, and economic opportunities through the power of bicycles.
  • By raffling these exclusive replica championship bicycles, World Bicycle Relief aims to raise critical funds to continue its mission.
  • To enter the raffle for a chance to win one of these four replica championship bicycles, simply support World Bicycle Relief through viprize.org/wbr .

Eblasakimab Monthly Dosing Shows Potential for Best-In-Class Therapy in Positive Phase 2b Study in Atopic Dermatitis

Retrieved on: 
torsdag, juli 6, 2023
Lead, Psoriasis Area and Severity Index, US Foods, Arm, ASLN, Aes, Atopic dermatitis, Eczema Area and Severity Index, Inflammation, Oregon Health and Science University Center for Women's Health, Type 2, Patient, SAN, Common, Trial, TREK, Upper respiratory tract infection, Headache, ITT, Conjunctivitis, Allergic inflammation, Food, Disease, Vaccine, Medical imaging, Pharmaceutical industry, Hydraulic machinery, Fertilizer, EASI, Dupilumab

Regimens dosing once every two weeks also met the primary endpoint with statistical significance, as well as meeting key secondary endpoints.

Key Points: 
  • Regimens dosing once every two weeks also met the primary endpoint with statistical significance, as well as meeting key secondary endpoints.
  • Eblasakimab was generally well-tolerated at all dose levels, with low rates of conjunctivitis and injection site reactions supporting the potential for a differentiated safety profile.
  • SAN MATEO, Calif. and SINGAPORE, July 06, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced positive topline data from its Phase 2b dose-ranging study of eblasakimab in adult patients with moderate-to-severe atopic dermatitis (AD), the TREK-AD (TRials with EblasaKimab in Atopic Dermatitis) study.
  • The Company is also conducting the TREK-DX (TRials in EblasaKimab in Dupilumab eXperienced AD patients) study of eblasakimab in dupilumab-experienced patients and expects to announce topline data from that study in 1Q 2024.

ASLAN Pharmaceuticals Announces $20M Private Placement Led by BVF Partners L.P. With the Potential to Receive Up to an Additional $80M

Retrieved on: 
fredag, februari 24, 2023
Power purchase agreement, TREK, Prospectus, Sales management, Purchasing, Patient, Exercise, SAN, ASLN, Sale, VWAP, ADS, Atopic dermatitis, Security (finance)

In addition, ASLAN will have the potential to receive up to an additional $80 million if all purchase warrants being issued in connection with the Purchase Agreement are fully exercised.

Key Points: 
  • In addition, ASLAN will have the potential to receive up to an additional $80 million if all purchase warrants being issued in connection with the Purchase Agreement are fully exercised.
  • ASLAN intends to use the net proceeds from the private placement for working capital and general corporate purposes, including the clinical development of eblasakimab and farudodstat.
  • Both tranches of the purchase warrants also include a mandatory exercise provision subject to the satisfaction of certain pre-specified conditions.
  • Any offering of the securities under the resale registration statement will only be made by means of a prospectus.

Tootl Transport Rolls Out Non-Emergency Medical Transportation Franchise

Retrieved on: 
fredag, februari 24, 2023
Transport, TREK, Trust, Interface (computing), Organization, Ageing, Kindness, Respect, Growth, Fishman, Adviser, Case management (mental health), PR, Empathy, Daci Temple, Disability, COVID, POSTNET, Management, Video game, Nursing, Tootling, Operation

NORTHBROOK, Ill., Feb. 24, 2023 /PRNewswire/ -- On a mission to fill the nation's growing need for safe, reliable wheelchair accessible transportation, Tootl Transport announced today it will begin to offer franchises in select markets around the country. 

Key Points: 
  • The booming Non-Emergency Medical Transportation (NEMT) sector was $8.6 billion in 2021, and is projected to nearly double and reach over $15 billion by 2028.
  • Their goal was to improve as many lives as possible by providing access to quality and reliable transportation for people of all abilities.
  • Brad and I couldn't be more excited to be involved in the journey of growing and supporting the Tootl franchise system."
  • Unlike more expensive traditional brick and mortar businesses, including the franchise fee, the initial investment for a Tootl franchise is between $78,400-$97,400.

Romios Gold Identifies Major Geophysical Target Beneath Newly Discovered Copper-Tungsten Skarn at The Trek South Project, Golden Triangle, BC

Retrieved on: 
onsdag, november 9, 2022
Honey, MT, Silver, Communication, Research, Induce, Video news release, Fig, IP, WO3, Company, Program, Ownership, La Corne, Forward-looking statement, Gold, 3D, Copper, Anomaly, News, TSX Venture Exchange, CEO, TSX, NSR, Equilateral triangle, Golden Triangle, Intrusive, National instrument, FSE, Trek, AND, Musselwhite, Magnetotellurics, Laboratory, Geology, Tungsten, L1, Copperhead, TREK, National Instrument 43-101, See, ALS, Kinkaid, Rare-earth element, Granite, Uranium, Silviculture, Surveying, Amusement arcade, Microscope, Names of the Greeks, BC, Facebook, Galore Creek mine

Romios' VP of Exploration, Mr. John Biczok, P. Geo, commented, "The 2022 Trek South summer program was very successful in defining a major geophysical (IP-MT) target underlying the centre of the >1 km wide porphyry-style Cu-Au zone that Romios discovered in 2021.

Key Points: 
  • Romios' VP of Exploration, Mr. John Biczok, P. Geo, commented, "The 2022 Trek South summer program was very successful in defining a major geophysical (IP-MT) target underlying the centre of the >1 km wide porphyry-style Cu-Au zone that Romios discovered in 2021.
  • Figure 1: Southeast looking orthogonal view of the Trek South 3D chargeability model derived from IP data.
  • Chargeability highs in red are believed to reflect sulphide mineralization beneath the exposed porphyry and skarn mineralization.
  • In July 2022, Simcoe Geoscience completed 3 lines of Alpha IPTM over the Trek South porphyry target and the newly discovered Cu-W skarn adjacent to it with very encouraging results.